The next generation biopharmaceuticals

Affibody AB and Creative Antibiotics AB enter collaboration to develop targeted antibiotics.

2012-02-02

Through the agreement Creative Antibiotics AB gains access to Affibody’s two proprietary technology platforms Affibody® molecules and Albumod™. Affibody® molecules are a novel class of antibody mimetics that have excellent efficacy, safety, and administration route benefits. Albumod™ is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.

The agreement consists of a defined protein target development collaboration and a product license agreement. Creative Antibiotics will be responsible for the future development of the products.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report Q2 (August 23, 2018)